Allergan plc Ordinary Shares (AGN) was Downgraded by Piper Jaffray to ” Neutral” while Lowering the Price Target of the company shares to $ 238 from a previous price target of $311 . Earlier the firm had a rating of “Overweight ” on the company shares. Piper Jaffray advised their investors in a research report released on Apr 18, 2016.
Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Morgan Stanley Resumed Allergan plc Ordinary Shares on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $300.Shares were Reiterated by UBS on Apr 7, 2016 to “Buy” and Lowered the Price Target to $ 300 from a previous price target of $366 .Allergan plc Ordinary Shares was Downgraded by Susquehanna to ” Neutral” on Apr 7, 2016.
On the company’s financial health, Allergan plc Ordinary Shares reported $3.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Feb 22, 2016. Analyst had a consensus of $3.32. The company had revenue of $4197.50 million for the quarter, compared to analysts expectations of $4179.62 million. The company’s revenue was up 73.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Allergan plc Ordinary Shares opened for trading at $217.56 and hit $220.65 on the upside on Friday, eventually ending the session at $217.16, with a gain of 0.36% or 0.77 points. The heightened volatility saw the trading volume jump to 51,86,971 shares. Company has a market cap of $85,710 M.
In a different news, on Dec 9, 2015, Nesli Basgoz (director) sold 2,300 shares at $312.96 per share price. According to the SEC, on Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price. On Aug 24, 2015, Paul Bisaro (Exec Chairman) purchased 1,000 shares at $297.42 per share price, according to the Form-4 filing with the securities and exchange commission.